最新ニュース ImmunityBio (NASDAQ:IBRX) 株価情報

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？Bilibili Inc.は（NASDAQ：BILI）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、21ドルの株価予測を発表しました。

中国配信大手ビリビリ　株価が23%の高騰

Biotech

Health Care

General

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；腺腫を伴う場合と伴わない場合があります。

FDAはImmunityBioの膀胱癌薬の承認を認め、株価が上昇

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。

ImmunityBio Inc

The United States and Ukraine have entered into an agreement to jointly invest in Ukraine&#8217;s mineral resources, oil, and gas sectors. This move reportedly fulfills a key request from the White House and provides crucial support to Ukraine.
What Happened: The newly established &#8220;United States-Ukraine Reconstruction Investment Fund&#8221; will facilitate collaboration between the two nations to boost Ukraine&#8217;s economic recovery. According to a Washington Post <a href="https://www.washingtonpost.com/">report</a> on Wednesday, Scott Bessent, the U.S. Treasury Secretary, highlighted the agreement&#8217;s importance in demonstrating the U.S. commitment to a free and prosperous Ukraine.
He said, &#8220;This agreement signals clearly to Russia that the Trump Administration is committed to a peace process centered on a free, sovereign, and prosperous Ukraine over the long term.&#8221;
Yulia Svyrydenko, Ukraine&#8217;s Minister of Economy, emphasized that the agreement reflects the U.S.&#8217;s dedication to Ukraine&#8217;s security and recovery. The document, seen by The Washington Post, underscores a strategic alignment between the countries, though it lacks specific security guarantees.
The agreement notably excludes&nbsp;the Zaporizhzhia nuclear power plant,&nbsp;which was seized by Russia in 2022. U.S. officials have suggested&nbsp;taking control of the plant&nbsp;in a future peace deal. Ukraine&#8217;s initial proposal under President&nbsp;Volodymyr Zelensky&nbsp;was revised after disagreements over security and financial terms.
The latest draft addresses Ukraine&#8217;s concerns about compliance with European Union laws and removes language requiring reimbursement for past U.S. military aid. Despite uncertainties, the deal is seen as a symbolic gesture of support, with private sector investment still needed for Ukraine&#8217;s mineral projects.
Alex Jacquez, a senior Biden-era minerals official, said that while Ukraine has deposits of a &#8220;variety of critical minerals&#8221; their valuation was largely imaginary.
&#8220;There is a reason few of these mining projects are actually being developed outside of China — under current economic conditions, it makes little sense for investors,&#8221; said Jacquez.
See Also: <a href="https://benzinga.com/25/04/45088889/mike-pence-says-trump-comeback-unrivaled-in-modern-american-history-but-only-return-to-values-of-first-term-will-" target="_blank" rel="noreferrer noopener">Mike Pence Says Trump Comeback &#8216;Unrivaled&#8217; In Modern American History But Only Return To Values Of First Term Will Ensure President&#8217;s Legacy</a>
Why It Matters: The agreement comes at a time when Ukraine&#8217;s recovery is heavily reliant on sustainable investment. Experts have called for a&nbsp;<a href="https://www.benzinga.com/government/regulations/25/03/44463509/ukraines-recovery-depends-on-sustainable-investment-experts-call-for-trilateral-minerals-deal">trilateral minerals deal</a>&nbsp;involving the U.S. and the European Union to secure Ukraine's critical mineral assets. Such a partnership could enhance supply chain security and provide geopolitical stability.
Additionally, the deal follows a period of tension between the U.S. and Ukraine. President Donald Trump previously expressed dissatisfaction with Zelenskyy after a <a href="https://in.benzinga.com/25/03/44064917/trump-says-ukraines-zelensky-is-not-ready-for-peace-after-oval-office-spat-he-disrespected-the-united-states-of-america">contentious meeting</a> at the White House, highlighting ongoing challenges in U.S.-Ukraine relations. Despite these challenges, the finalized agreement marks a step forward in economic collaboration.
Photo Courtesy: LanKS on Shutterstock.com
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

US, Ukraine Sign Minerals Deal: Scott Bessent Says Agreement Is A Clear Sign To Russia That Trump Administration Wants A 'Free And Prosperous' Kyiv

PTPI

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

WIIM

SCI stock has given up its prior gain. Service Corp International shares were trading higher after the company reported better-than-expected Q1 financial results and issued FY25 adjusted EPS guidance with its midpoint above estimates.

OMF stock has given up its prior loss. OneMain Holdings shares were trading lower on possible continued weakness after the company reported a Q1 sales miss on Tuesday.

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 15 years by 15.6% on an annualized basis producing an average annual return of 26.79%. Currently, Comfort Systems USA has a market capitalization of $14.02 billion. 
Buying $100 In FIX: If an investor had bought $100 of FIX stock 15 years ago, it would be worth $3,285.54 today based on a price of $397.55 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746054013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://www.cnbc.com/2025/04/30/court-finds-apple-executive-lied-under-oath.html" title="https://www.cnbc.com/2025/04/30/court-finds-apple-executive-lied-under-oath.html">https://www.cnbc.com/2025/04/30/court-finds-apple-executive-lied-under-oath.html</a>

Legal

AAPL

'Court Finds Apple, Executive Lied Under Oath In Epic Games Trial' - CNBC

Barclays analyst Trevor Young maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Equal-Weight and lowers the price target from $55 to $53.

Price Target

Analyst Ratings

ETSY

Barclays Maintains Equal-Weight on Etsy, Lowers Price Target to $53

Barclays analyst Brandon Oglenski maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Overweight and lowers the price target from $135 to $125.

Barclays Maintains Overweight on XPO, Lowers Price Target to $125

Barclays analyst George Wang maintains Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) with a Underweight and lowers the price target from $188 to $152.

GRMN

Barclays Maintains Underweight on Garmin, Lowers Price Target to $152

RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 14.68%. Currently, RB Global has a market capitalization of $18.63 billion. 
Buying $100 In RBA: If an investor had bought $100 of RBA stock 10 years ago, it would be worth $392.29 today based on a price of $100.66 for RBA at the time of writing.
<h3>RB Global's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746053111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In RB Global 10 Years Ago Would Be Worth This Much Today

Barclays analyst Tim Long maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Equal-Weight and lowers the price target from $326 to $263.

ZBRA

Barclays Maintains Equal-Weight on Zebra Technologies, Lowers Price Target to $263

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $161 to $171.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171

Barclays analyst Saket Kalia maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Equal-Weight and lowers the price target from $40 to $33.

TENB

Barclays Maintains Equal-Weight on Tenable Holdings, Lowers Price Target to $33

Barclays analyst Jeffrey Bernstein maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Overweight and lowers the price target from $87 to $77.

Barclays Maintains Overweight on Sysco, Lowers Price Target to $77

Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) reported <a href="https://www.benzinga.com/topic/samsung" target="_blank" rel="noreferrer noopener">first-quarter revenue</a> growth of 10% year-on-year to 79.1 trillion Korean won ($55.5 billion) Wednesday.
Revenue growth marked an all-time quarterly high, driven by strong sales of flagship Galaxy S25 smartphones and <a target="_blank" href="https://www.samsung.com/global/ir/" rel="noreferrer noopener">high-value-added products</a>.
Operating profit was 6.7 trillion Korean won ($17.62 billion), up from 6.6 Korean won a year ago, despite headwinds for the DS Division.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44630345/samsungs-china-chip-pivot-gains-steam-with-54-export-surge-amid-us-market-struggles" rel="noreferrer noopener">Samsung&#8217;s China Chip Pivot Gains Steam With 54% Export Surge Amid US Market Struggles</a>
The DS Division (encompassing Memory and S.LSI / Foundry) posted revenue of 25.1 trillion Korean won (versus 23.1 trillion Korean won Y/Y).
The division reported 1.1 trillion Korean won in operating profit (versus 1.9 trillion Korean won Y/Y) due to the erosion of average selling price (ASP) and a decrease in HBM sales due to export controls on AI chips and deferred demand in anticipation of upcoming enhanced HBM3E products.
Samsung Display Corp Division (SDC) posted 5.9 trillion Korean won in revenue (versus 5.4 trillion Korean won Y/Y) and 0.5 trillion Korean won in operating profit (versus 0.3 trillion Korean won Y/Y).
The Mobile eXperience (MX) and Networks businesses posted 37.0 trillion Korean won in revenue (versus 33.5 Korean won Y/Y). The division reported 4.3 trillion Korean won in operating profit (versus 3.5 trillion Korean won Y/Y).
The quarterly capex was 12.13 trillion Korean won, down from 13.42 trillion Korean won a year ago.
Samsung&#8217;s flagship products, including semiconductors, smartphones, and tablets, are now exempt from reciprocal tariffs. Still, President Donald Trump has&nbsp;indicated&nbsp;that a tariff on the electronics supply chain, including chips, is in the works, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-30/samsung-s-chips-business-beats-estimates-after-stockpiling-push?sref=TBDibEcD" rel="noreferrer noopener">reported</a> Wednesday.
Seoul and Washington agreed to pursue a comprehensive package agreement by July 8, when the 90-day tariff pause will end.
Samsung has struggled for months to secure&nbsp;Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) final nod for its most advanced HBM products, making it challenging to compete with&nbsp;Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Samsung is in talks to supply customized sixth-generation high-bandwidth memory, or HBM4, chips to major AI chipmakers, including Nvidia, Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, the Korea Economic Daily <a target="_blank" href="https://www.kedglobal.com/korean-chipmakers/newsView/ked202504300004" rel="noreferrer noopener">reported</a> Wednesday.
Outlook: In the second quarter, the Memory Business anticipates robust demand for AI servers and a ramp-up of the enhanced HBM3E 12H.
AI-related demand is expected to remain high in the second half, in conjunction with the launch of new GPUs.
In the second quarter, the System LSI Business will maintain steady revenue by gaining SoC adoption by a major customer for new flagship models and capitalizing on the growing adoption of 200-megapixel sensors.
In the second half, the System LSI Business will expand its flagship SoC supply and develop its automotive sensor portfolio.
In the second quarter, the Foundry Business will stabilize its 2nm process production and drive earnings improvement by actively addressing strong mobile and automotive demand in the United States. Looking ahead to the second half, the Foundry Business aims to start 2nm mass production, secure major 2nm orders, and strengthen its specialty process portfolio on mature nodes.
In the second quarter, the mobile display business maintained a conservative outlook on earnings while pursuing a stable supply of new products such as foldables.
In the second half, SDC aims to grow mobile display business sales through differentiated technologies and products.
In the second quarter, MX Business plans to sustain flagship-centric sales amid weak seasonality by successfully launching the Galaxy S25 Edge. It will also expand its AI smartphone lineup by introducing &#8220;Awesome Intelligence&#8221; to the Galaxy A series.
In the second half, the MX Business will strengthen its foldable lineup by offering a differentiated AI user experience. In addition, the Business will launch new ecosystem products with enhanced AI and health capabilities and explore new product segments such as XR.
In the second quarter, Visual Display and Digital Appliances intends to expand TV sales with its 2025 AI TV lineup and the integration of advanced AI functions.
In the second half, the Business will focus on capturing peak season demand through strategic collaboration with distributors based on an enhanced AI TV lineup.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44140452/gm-stellantis-supplier-samsung-sdi-weighs-new-us-battery-plant-amid-trumps-ev-policy-shift" target="_blank" rel="noreferrer noopener">GM, Stellantis Supplier Samsung SDI Weighs New US Battery Plant Amid Trump&#8217;s EV Policy Shift</a></li>
</ul>

Asia

Earnings

Guidance

Emerging Markets

Tech

Media

AVGO

GOOG

GOOGL

NVDA

SSNLF

Samsung Galaxy Sales Soar But Foundry Segment Lags As Trump Tariffs Loom

Barclays analyst George Wang maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Equal-Weight and lowers the price target from $59 to $34.

SMCI

Barclays Maintains Equal-Weight on Super Micro Computer, Lowers Price Target to $34

Barclays analyst Jeffrey Bernstein maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and lowers the price target from $106 to $98.

SBUX

Barclays Maintains Overweight on Starbucks, Lowers Price Target to $98

Barclays analyst Kannan Venkateshwar maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $710 to $650.

SPOT

Barclays Maintains Overweight on Spotify Technology, Lowers Price Target to $650

Barclays analyst Terry Ma maintains SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Equal-Weight and raises the price target from $11 to $12.

SOFI

Barclays Maintains Equal-Weight on SoFi Technologies, Raises Price Target to $12

Barclays analyst Tom O'Malley maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Equal-Weight and raises the price target from $80 to $90.

Barclays Maintains Equal-Weight on Seagate Tech Hldgs, Raises Price Target to $90

Press Releases

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, LLP Investigates Claims on Behalf of Investors

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors

ImmunityBio to Host Investor Day

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

DRVN

WOLF

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

Immunovant

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

HC Wainwright & Co.

D. Boral Capital

BTIG

EF Hutton

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？
<ol>
<li>Bilibili Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、<a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener">21ドルの株価予測を発表しました</a>。</li>
<li>ImmunityBio, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>）の株は、複数の州でのANKTIVAの保険適用の発表後、22.36%上昇しました。<a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener">最初の商用用量が投与されました</a>。</li>
<li>Sasol Ltd.は（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>）の株は、この会社が裁判所の判決を受け、TotalEnergies SE（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>）マーケティングの訴えを認められたことを発表した後、20.89%上昇しました。また、同社は損害に対して39億ランド（約389億円）と、利息に対して約23億ランド（約230億円）を受領しました。<a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener">and approximately R2.3B in interest</a>。</li>
<li>Ollie&#8217;s Bargain Outlet Holdings Inc（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>）の株は、先週JPモルガンが株をニュートラルからオーバーウェイトに格上げした後、15.25%上昇しました。</li>
<li>Intra-Cellular Therapies Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>）の株は、この会社が主要な抗うつ症状を持つ患者を対象として、補助療法としてLumateperoneを評価する第2相3試験のトップライン結果を発表した後、13.18%上昇しました。<a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">meeting primary and key secondary endpoints</a>。</li>
<li>Amkor Technology, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>）の株は、チップ株の強さ全体で12.06%上昇しました。また、B.ライリー証券のアナリストは、<a href="https://www.benzinga.com/quote/AMKR/analyst-ratings">アナリストレーティング</a>を45ドルから50ドルに株価予測を引き上げました。</li>
<li>IRhythm Technologies, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>）の株は、製造自動化の初期フェーズを発表後、11.53%上昇しました。</li>
<li>Rocket Lab USA, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>）の株は、<a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">東京の日本の会社シンペクティブとの10回の打ち上げ契約を締結した後、11.32%上昇しました。</a></li>
<li>Bread Financial Holdings, Inc.（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>）の株は、Evercore ISI Groupが株をアンダーパフォームからインラインに格上げし、その価格ターゲットを42ドルから45ドルに引き上げた後、10.81%上昇しました。また、RBCキャピタルは株に対してセクターパフォームの格付けを維持し、その <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">45ドル</a>まで<a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">38ドル</a>。</li>
<li>BRF S.A.は（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>）の株は、10.69%上昇しました。</li>
</ol>
ウィキメディア・コモンズより
その他の記事: <a href="https://www.benzinga.com/news/24/06/39447506/gamestop-and-first-solar-were-among-the-10-biggest-large-cap-losers-last-week-june-16-june-22-are-th">先週の大型株の10大下落銘柄（6月16日～6月22日）</a>

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；<a href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" target="_blank" rel="noopener noreferrer">腺腫を伴う場合と伴わない場合があります</a>。
この薬は、結核の治療に使われているBCGワクチンと組み合わされています。また、特定の膀胱癌の形態の治療法としても使用されています。
昨年5月に、FDAはAnktivaとBCGの治療法について、米国食品医薬品局の第三者<a href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" target="_blank" rel="noopener noreferrer">契約製造企業</a>の検査中に見つかった欠陥を理由に、一次審査通過に関する完全回答書を発行しました。
「FDAによるANKTIVAの承認は、私たちがチェックポイント阻害剤を超える次世代の免疫療法を開始することを示しています」と、ImmunityBioのエグゼクティブチェアマンでグローバルチーフサイエンティフィック・アンド・メディカル・オフィサーのパトリックスンションク氏は述べています。 
同社によると、AnktivaはCISを伴うNMIBCの最初のIL-15アゴニスト免疫療法であり、FDAは、完全反応（CR）と完全反応継続期間（DOR）の安全性と有効性の結果に基づく、相当な成果が出るとして、同薬に対して早期開発薬指定と承認を付与しました。 
CRの率は、77人の患者のうちの評価可能な患者数で62%で、その信頼区間の上限は73%です。 
2023年11月時点の完全反応の期間は、最大で47ヶ月以上で、現在も継続中です。 
同社は、ANKTIVAとBCGとの間に見られた完全反応の期間の長期化は、IBCどくの専門家のパネルが提案する意義のある臨床結果の基準を上回っているとしています。
この反応の持続期間は今も継続中であり、したがって反応の最終中央値の期間は確定していません。CRが確認された患者のうち、58%がDORが12ヶ月以上であり、40%がDORが24ヶ月以上です。
Anktivaは、2024年5月の中旬までには米国で利用可能になる予定です。
株価動向：IBRX株は、最終確認時点の火曜日の午後5.17ドルで4.65%上昇しています。

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；<a href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" target="_blank" rel="noopener noreferrer">腺腫を伴う場合と伴わない場合があります</a>。
この薬は、結核の治療に使われているBCGワクチンと組み合わされています。また、特定の膀胱癌の形態の治療法としても使用されています。
昨年5月に、FDAはAnktivaとBCGの治療法について、米国食品医薬品局の第三者<a href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" target="_blank" rel="noopener noreferrer">契約製造企業</a>の検査中に見つかった欠陥を理由に、一次審査通過に関する完全回答書を発行しました。
「FDAによるANKTIVAの承認は、私たちがチェックポイント阻害剤を超える次世代の免疫療法を開始することを示しています」と、ImmunityBioのエグゼクティブチェアマンでグローバルチーフサイエンティフィック・アンド・メディカル・オフィサーのパトリックスンションク氏は述べた。
同社によると、AnktivaはCISを伴うNMIBCの最初のIL-15アゴニスト免疫療法であり、FDAは、完全反応（CR）と完全反応継続期間（DOR）の安全性と有効性の結果に基づく、相当な成果が出るとして、同薬に対して早期開発薬指定と承認を付与しました。
CRの率は、77人の患者のうちの評価可能な患者数で62%で、その信頼区間の上限は73%です。
2023年11月時点の完全反応の期間は、最大で47ヶ月以上で、現在も継続中です。
同社は、ANKTIVAとBCGとの間に見られた完全反応の期間の長期化は、IBCどくの専門家のパネルが提案する意義のある臨床結果の基準を上回っているとしています。
この反応の持続期間は今も継続中であり、したがって反応の最終中央値の期間は確定していません。CRが確認された患者のうち、58%がDORが12ヶ月以上であり、40%がDORが24ヶ月以上です。
Anktivaは、2024年5月の中旬までには米国で利用可能になる予定です。
株価動向：IBRX株は、最終確認時点の火曜日の午後5.17ドルで4.65%上昇しています。

Comments

ImmunityBio

ニュース

最新ニュース ImmunityBio (NASDAQ:IBRX) 株価情報

月曜日, 6 24, 2024

金曜日, 4 26, 2024

火曜日, 4 23, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル